Biotech | August 14, 2021
Bharat Biotech’s first nasal vaccine gets approval for Phase 2 trials
This is the first of its kind vaccine for Covid 19 to get the go-ahead
This is the first of its kind vaccine for Covid 19 to get the go-ahead
The company is confident of commencing production at both Mahad and Chiplun units soon
Revenues from operations for FY21 stood at Rs. 202.38 crore as compared to 167.27 crore, up by 21%
In some countries such as France, Italy, Spain and the Balkan region, Menarini Group will lead the commercialisation effort, as part of an exclusive licensing agreement signed with Glenmark
Lasa Supergenerics Limited has received WHO GMP Certificate for its manufacturing facility situated at Khed in Ratnagiri.
Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression
The company reported sustained increase in formulations' share despite slowdown in productivity of Gagillapur facility
This global affiliation marks a critical step in the company’s mission to create long-term value through ethical practices, scientific innovation, and inclusive healthcare delivery
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
The company's first-ever corporate-level submission to EcoVadis builds on years of operational and environmental excellence
Subscribe To Our Newsletter & Stay Updated
